Trial
NCT03618160
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Janssen Pharmaceutical K.K.
Collaborators
—
Condition
Healthy
Intervention
JNJ-64565111
Why stopped
The results of leading Phase 2 trials did not meet all desired endpoints
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-03